Beijing Leadman Biochemistry Co (300289) Fair Value & Analysis
Healthcare · CN · Market cap 3.3B CNY
Fair value as of: Jul 9, 2026
From 13 valuation models · updated 32 days ago
Share price +6.0% over the past month.
A solid business, but screening 71% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥1.87). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥3.55 – ¥11.33 · fair‑value band ¥1.17 – ¥1.87 · the ¥5.87 price screens above the ¥1.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Beijing Leadman Biochemistry Co (300289) currently trades at ¥5.87, while our model-based Fair Value estimate is ¥1.70, implying the stock looks roughly 71.0% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Beijing Leadman Biochemistry Co generated revenue of 318M CNY at a net margin of -8.1%. Revenue declined 10.7% year over year. It earns a return on equity of -1.6%. The balance sheet holds a net cash position of 574M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥1.17 (bear case) to ¥1.87 (bull case); at ¥5.87, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -71%, 300289 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Asset-Based (¥2.02) versus Dividend Discount (¥0.1000). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China.
Full company description
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnology, clinical diagnosis, drug development, chemical production, and other related applications. It also provides biochemical reagents for liver function, lipid profile, diabetes reagents, pancreas function, tumor detection, protein and others, multi calibrators and multi co, semi-quantitative assays, coagulation reagents, cardiac marker, cardiac reagents, electrolytes, and renal function; companion reagents regents for tumor, thyroid hormone, sex hormone, infectious disease, and others; and IDS-compatible luminescent reagents. In addition, it offers testing instruments. Beijing Leadman Biochemistry Co.,Ltd. was founded in 1997 and is based in Beijing, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beijing Leadman Biochemistry Co reported revenue of ¥326M in FY2025 versus ¥564M in FY2021, a compound −12.8%/yr. Reported net income was −¥23.0M in FY2025.
300289 screens 71% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Beijing Leadman Biochemistry Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beijing Leadman Biochemistry Co (300289) overvalued or undervalued?
What is the fair value of 300289?
What is the quality score of 300289?
What is the revenue of Beijing Leadman Biochemistry Co (300289)?
What is the net profit margin of 300289?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beijing Leadman Biochemistry Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.